Indaptus Therapeutics, Inc.
INDP
$2.48
$0.4522.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.67M | 5.31M | 1.13M | 2.29M | 1.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.16M | 8.16M | 2.65M | 4.46M | 4.57M |
| Operating Income | -2.16M | -8.16M | -2.65M | -4.46M | -4.57M |
| Income Before Tax | -2.54M | -8.11M | -2.98M | -5.23M | -4.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.54M | -8.11M | -2.98M | -5.23M | -4.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.54M | -8.11M | -2.98M | -5.23M | -4.53M |
| EBIT | -2.16M | -8.16M | -2.65M | -4.46M | -4.57M |
| EBITDA | -- | -8.16M | -2.65M | -4.46M | -4.57M |
| EPS Basic | -0.23 | -4.51 | -2.98 | -9.10 | -9.11 |
| Normalized Basic EPS | -0.15 | -2.82 | -1.87 | -5.68 | -5.69 |
| EPS Diluted | -0.23 | -4.51 | -2.98 | -9.10 | -9.11 |
| Normalized Diluted EPS | -0.15 | -2.82 | -1.87 | -5.68 | -5.69 |
| Average Basic Shares Outstanding | 10.96M | 1.80M | 997.00K | 574.90K | 497.80K |
| Average Diluted Shares Outstanding | 10.96M | 1.80M | 997.00K | 574.90K | 497.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |